Sign in

You're signed outSign in or to get full access.

John C. Ball

President, Treasurer, and Principal Financial and Accounting Officer at Gabelli Healthcare & WellnessRx Trust
Executive

About John C. Ball

John C. Ball is the President, Treasurer, and Principal Financial and Accounting Officer of The Gabelli Healthcare & WellnessRx Trust (GRX), serving since 2017; his officer term is indefinite until resignation/retirement or successor election . He was born in 1976 and also holds external roles as Senior Vice President of GAMCO Investors, Inc. (since 2018) and Chief Executive Officer of G.distributors, LLC (since 2020) . The 2025 proxy lists his titles and tenure but does not disclose education, TSR, revenue, or EBITDA performance metrics for GRX officers . As of December 31, 2024, Ball beneficially owned 26 GRX common shares (<1% of outstanding), indicating limited direct economic exposure; the Fund reported that Section 16(a) filers complied during 2024 .

Past Roles

OrganizationRoleYearsStrategic Impact
Gabelli Fund Complex (registered investment companies)OfficerSince 2017 Not disclosed

External Roles

OrganizationRoleYearsStrategic Impact
GAMCO Investors, Inc.Senior Vice PresidentSince 2018 Not disclosed
G.distributors, LLCChief Executive OfficerSince 2020 Not disclosed

Fixed Compensation

  • The proxy’s compensation table covers Trustees and officers “if any, who were compensated by the Fund rather than the Adviser” for FY2024; John C. Ball is not listed, indicating no GRX-paid compensation disclosed for him in 2024 (compensation paid by the Adviser is not disclosed in this proxy) .
  • Trustee retainers and meeting fees are specified, but officer cash compensation beyond the one listed (Bethany Uhlein) is not provided; no base salary, target bonus, or actual bonus for Ball are disclosed in the proxy .

Performance Compensation

  • No disclosure for Ball’s incentive design (metrics, weighting, targets/actuals, payout, or vesting) in the GRX proxy .

Equity Ownership & Alignment

MetricAs of Dec 31, 2024
Common Shares Beneficially Owned26 shares
Percent of Shares Outstanding<1% (asterisk denoting less than 1%)
Preferred Shares Beneficially OwnedNone disclosed for Ball
Vested vs. Unvested SharesNot disclosed
Options (Exercisable/Unexercisable, ITM Value)Not disclosed
Shares Pledged as CollateralNot disclosed
Stock Ownership Guidelines (officers)Not disclosed in the proxy

Context: On the record date, GRX had 15,498,074 common shares outstanding; the proxy uses coded dollar ranges and asterisks for percentage disclosure, with Ball disclosed at 26 shares and “*” denoting less than 1% .

Employment Terms

TermDisclosure
Officer TitlesPresident, Treasurer, Principal Financial and Accounting Officer
Start Date / TenureSince 2017; officer service listed as “Since 2017”
Term LengthIndefinite; holds office until resignation/retirement or successor is elected and qualified
Employment AgreementNot disclosed
SeveranceNot disclosed
Change-of-ControlNot disclosed
ClawbacksNot disclosed
Non-compete / Non-solicitNot disclosed
Deferred Compensation / Pension / SERPNot disclosed
PerquisitesNot disclosed

Risk Indicators & Governance Notes

  • Section 16(a) compliance: Based solely on Forms 3/4 reviews, the Fund believes covered persons complied with filing requirements during FY2024 .
  • Control share statute: The proxy provides extensive context on Delaware Statutory Trust Act control share acquisition provisions applicable to GRX; although governance-relevant, no officer-specific restrictions or pledging/hedging disclosures for Ball are provided .
  • Meeting attendance and governance processes are described at the Board level, but Ball is not a Trustee and thus not tied to committee roles in this proxy .

Investment Implications

  • Limited skin-in-the-game: Ball’s direct beneficial ownership is 26 GRX common shares (<1%), suggesting modest personal alignment with common shareholders; the proxy does not disclose officer ownership guidelines or pledging for Ball, constraining alignment assessment .
  • Pay transparency gap: GRX’s proxy reports trustee compensation and notes officers “if any” paid by the Fund, but provides no cash or equity compensation detail for Ball—reducing visibility into pay-for-performance linkages and potential vesting-related selling pressure .
  • Retention risk appears low from governance mechanics alone: Ball’s officer term is indefinite until resignation/retirement or successor election, and there are no disclosed severance/change‑of‑control terms that might create departure incentives; however, absence of disclosures limits a definitive view on retention economics .
  • Trading signals: No Form 4 activity, option grants, or vesting schedules disclosed in this proxy for Ball; without insider trading data, there are no document‑based indicators of near‑term selling pressure .